Erlotinib/Gefitinib with Bevacizumab for Advanced Lung Cancer
Real World Study to Evaluate the Efficacy and Resistant Mechanism of Erlotinib/Gefitinib Combined With Bevacizumab in First Line EGFR Mutation Positive Advanced Non-aquamous Non-small Cell Lung Cancer
This study is testing whether combining two cancer drugs, Erlotinib or Gefitinib, with Bevacizumab can help people with advanced lung cancer who have a specific gene mutation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Drugs / interventions | bevacizumab, Erlotinib, Gefitinib |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT03647592 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness and safety of combining Erlotinib or Gefitinib with Bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have an EGFR mutation. It aims to analyze real-world outcomes, explore new mechanisms of drug resistance, and assess the consistency of gene testing results from tissue and plasma samples. The study will also evaluate the predictive value of dynamic plasma gene mutation profiles in relation to disease progression.
Who should consider this trial
Good fit: Ideal candidates include patients with advanced non-squamous NSCLC who have an EGFR mutation and are receiving their primary treatment.
Not a fit: Patients with other gene mutations or those with squamous cell lung cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a more effective treatment option for patients with advanced non-small cell lung cancer and improve understanding of drug resistance mechanisms.
How similar studies have performed: While this study explores a combination of existing treatments, similar approaches have shown promise in other studies, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * EGFR mutation(19del/L858R) * advanced non-saquamous non-small cell lung cancer * primary treatment of first diagnosis * performance status（0-1) Exclusion Criteria: * other genes mutation * saquamous
Where this trial is running
Changsha, Hunan
- Hunan Provincal Tumor Hospital — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Yongchang Z MD, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.